Skip to main content

Incyte Licenses Microarray Patents to Point Technologies

NEW YORK, June 24 -Incyte has licensed its microarray fabrication patents to Point Technologies, of Boulder, Colo., the companies said late Monday.

 

These patents, which Incyte has previously licensed to Agilent technologies, include US Patent No. 5,807,522, and US Patent No. 6,110,426. Both are entitled  "Methods for Fabricating Microarrays of Biological Samples," and cover the fabrication of a nucleic acid microarray by tapping the tip of a dispensing device against a solid support.

 

Point Technologies manufactures spotting pins for semiconductor manufacturing and microarray spotters. The patent licenses are intended to enable buyers of these spotting pins who use them in their own home-made microarraying devices, as well as those who manufacture arrayers, to use these pins for microarraying without infringing Incyte's patents, Point Technologies said.

 

Although Incyte continues to license out its microarray patents, the company exited the microarray manufacturing business in late 2001.

 

Separately, Incyte said today it had hired Richard De Schutter as chairman of its board of directors. De Schutter, a former chairman and CEO of DuPont, has served on Incyte's board since January 2002.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.